JW Pharmaceutical Corporation
KRX:001060.KS
23250 (KRW) • At close January 15, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 748,526.708 | 684,351.099 | 606,584.945 | 547,335.708 | 511,335.343 | 537,181.974 | 502,918.587 | 467,465.121 | 434,352.38 | 412,791.235 | 394,182.302 | 397,084.759 | 431,007.281 | 443,275.672 | 455,146.86 | 437,648.38 | 385,010.282 |
| Cost of Revenue
| 412,854.312 | 396,396.562 | 372,208.611 | 369,810.084 | 350,215.956 | 340,141.765 | 314,286.149 | 294,121.425 | 273,729.078 | 261,517.59 | 249,698.749 | 268,107.253 | 283,012.555 | 281,782.92 | 269,092.203 | 246,933.993 | 202,053.18 |
| Gross Profit
| 335,672.396 | 287,954.538 | 234,376.333 | 177,525.624 | 161,119.386 | 197,040.209 | 188,632.438 | 173,343.696 | 160,623.302 | 151,273.644 | 144,483.553 | 128,977.506 | 147,994.726 | 161,492.752 | 186,054.657 | 190,714.387 | 182,957.102 |
| Gross Profit Ratio
| 0.448 | 0.421 | 0.386 | 0.324 | 0.315 | 0.367 | 0.375 | 0.371 | 0.37 | 0.366 | 0.367 | 0.325 | 0.343 | 0.364 | 0.409 | 0.436 | 0.475 |
| Reseach & Development Expenses
| 33,671.364 | 33,736.273 | 19,883.612 | 22,943.262 | 25,219.508 | 21,268.397 | 21,981.548 | 18,004.761 | 16,480.04 | 17,481.959 | 13,464.234 | 12,356.865 | 12,005.132 | 5,828.155 | 6,047.78 | 5,715.418 | 5,915.061 |
| General & Administrative Expenses
| 116,774.631 | 91,222.177 | 86,214.499 | 65,839.732 | 41,933.287 | 64,723.268 | 60,281.842 | 59,665.538 | 54,018.861 | 52,309.813 | 47,912.512 | 33,089.179 | 32,739.117 | 28,960.655 | 26,476.987 | 25,802.158 | 23,745.822 |
| Selling & Marketing Expenses
| 35,864.473 | 35,515.62 | 29,123.722 | 26,679.685 | 39,779.234 | 26,829.347 | 24,788.642 | 23,848.417 | 21,080.793 | 19,646.579 | 18,282.896 | 20,620.525 | 23,818.606 | 26,509.9 | 44,414.573 | 49,946.706 | 44,646.854 |
| SG&A
| 152,639.104 | 126,737.797 | 115,338.221 | 92,519.417 | 81,712.521 | 91,552.615 | 85,070.484 | 83,513.955 | 75,099.654 | 71,956.392 | 66,195.408 | 53,709.704 | 56,557.723 | 55,470.555 | 70,891.56 | 75,748.864 | 68,392.676 |
| Other Expenses
| 48,928.158 | 64,701.407 | 67,954.651 | 63,385.927 | 73,201.188 | 881.196 | 1,952.388 | -1,558.541 | 523.106 | -49.864 | 1,331.62 | 333.47 | 73.195 | -8,420.894 | -9,672.482 | -9,557.032 | -10,072.173 |
| Operating Expenses
| 235,238.626 | 225,175.477 | 203,176.484 | 178,848.606 | 180,133.217 | 175,456.126 | 166,914.304 | 148,805.765 | 139,098.532 | 133,163.662 | 118,583.511 | 119,491.441 | 131,510.546 | 132,329.421 | 148,872.932 | 154,043.362 | 141,696.164 |
| Operating Income
| 100,303.77 | 62,960.871 | 31,199.849 | -5,475.956 | -19,013.831 | 21,584.083 | 21,718.134 | 24,537.931 | 21,524.771 | 18,109.983 | 25,900.042 | 9,486.065 | 16,623.268 | 29,163.332 | 37,181.725 | 36,671.029 | 41,260.939 |
| Operating Income Ratio
| 0.134 | 0.092 | 0.051 | -0.01 | -0.037 | 0.04 | 0.043 | 0.052 | 0.05 | 0.044 | 0.066 | 0.024 | 0.039 | 0.066 | 0.082 | 0.084 | 0.107 |
| Total Other Income Expenses Net
| -46,088.376 | -17,598.918 | -10,667.189 | -11,882.193 | -15,321.351 | -11,349.86 | -23,066.169 | -17,456.617 | -19,468.138 | -17,319.811 | -22,493.894 | -24,637.907 | -28,106.075 | -20,235.425 | -20,861.39 | -17,354.018 | -19,814.711 |
| Income Before Tax
| 54,215.394 | 45,361.952 | 20,532.661 | -13,205.175 | -34,335.182 | 10,234.223 | -1,348.035 | 7,081.315 | 2,056.633 | 1,860.916 | 3,406.148 | -15,151.842 | -11,482.808 | 8,927.907 | 16,320.335 | 19,317.011 | 21,446.228 |
| Income Before Tax Ratio
| 0.072 | 0.066 | 0.034 | -0.024 | -0.067 | 0.019 | -0.003 | 0.015 | 0.005 | 0.005 | 0.009 | -0.038 | -0.027 | 0.02 | 0.036 | 0.044 | 0.056 |
| Income Tax Expense
| 16,406.19 | 15,509.392 | 21,974.114 | 2,070.295 | -9,060.166 | 2,177.334 | -605.56 | 18,014.858 | 95.206 | 414.039 | 1,131.268 | 5,241.759 | -1,679.212 | 3,327.635 | 5,401.618 | 12,883.833 | 12,685.181 |
| Net Income
| 37,006.334 | 31,891.679 | -1,441.453 | -15,275.47 | -25,275.016 | 8,056.889 | -742.474 | -10,933.544 | 1,961.427 | 1,446.877 | 2,274.88 | -20,393.601 | -9,803.596 | 5,600.272 | 10,918.718 | 6,433.178 | 8,761.048 |
| Net Income Ratio
| 0.049 | 0.047 | -0.002 | -0.028 | -0.049 | 0.015 | -0.001 | -0.023 | 0.005 | 0.004 | 0.006 | -0.051 | -0.023 | 0.013 | 0.024 | 0.015 | 0.023 |
| EPS
| 1,426.36 | 1,267.1 | -62.11 | -657.85 | -1,088.93 | 298.53 | -65.33 | -515.81 | 57.77 | -164.26 | 131.38 | -1,360.42 | -679.72 | 377.2 | 732.43 | 427.89 | 505.18 |
| EPS Diluted
| 1,426.36 | 1,267.1 | -62.11 | -657.85 | -1,088.93 | 298.53 | -65.33 | -515.81 | 57.77 | -164.26 | 131.38 | -1,360.42 | -679.72 | 377.2 | 732.43 | 427.89 | 505.18 |
| EBITDA
| 89,221.681 | 73,454.376 | 45,129.658 | 15,070.135 | -2,867.647 | 39,336.572 | 27,280.238 | 38,908.594 | 36,779.157 | 34,689.343 | 39,648.9 | 23,059.882 | 26,065.603 | 35,216.985 | 39,839.271 | 40,791.241 | 41,060.977 |
| EBITDA Ratio
| 0.119 | 0.121 | 0.078 | 0.028 | -0.005 | 0.072 | 0.053 | 0.073 | 0.074 | 0.083 | 0.104 | 0.063 | 0.065 | 0.07 | 0.094 | 0.084 | 0.107 |